Lifecore Biomedical
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 484
- Market Cap
- $146.4M
- Introduction
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.
Earnings call transcript: Lifecore Biomedical Q2 2024 sees revenue growth, stock price drop
Lifecore Biomedical reported Q2 fiscal 2024 revenue of $32.6M, an 8% YoY increase, but faced a $6.6M net loss. Despite revenue growth, the earnings miss led to a 10.36% stock price drop. The company focuses on capacity expansion and development programs for future growth, maintaining its revenue guidance for the fiscal year.
Lifecore Biomedical Hosts Virtual Investor Day
Lifecore Biomedical hosted a virtual investor day, discussing business and growth strategy. A replay is available on their investor webpage.
Lifecore Biomedical to Report Financial Results for First
Lifecore Biomedical, Inc. (NASDAQ: LFCR) will report Q1 FY2025 financial results on Oct 4, 2024, prior to market open, hosting a webcast at 8:30 a.m. ET. The webcast will discuss Q1 financial results and recent corporate developments. Visit https://ir.lifecore.com/events-presentations for live and archived webcasts.
© Copyright 2025. All Rights Reserved by MedPath